We now show that the activation of JAK2/STAT3 may be a pre-requisite for EGF-induced EMT in these ovarian cancer cell lines, as pharmacological inhibition of JAK2 in ovarian cancer cells not only led to an inhibition of STAT3 activation but also inhibition of EGF-induced EMT phenotypes. This evidence concerns the gene EGF and ovarian cancer.